文献速递肝病消化道肿瘤与早癌

计算发现氯硝柳胺乙醇胺盐:一种通过抑制细胞分裂周期37信号在体外和小鼠中减少肝细胞癌细胞生长的老药新用候选药物

Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
PubMed 文献 · Gastroenterology · 2017-03-08

研究者检索公共数据库的基因表达特征以寻找抗肝细胞癌(HCC)药物,鉴定出驱虫药氯硝柳胺及其乙醇胺盐(NEN)。NEN的口服生物利用度高于氯硝柳胺,能减缓基因诱导性肝肿瘤和患者来源异种移植瘤的生长,且NEN与索拉非尼联用比单药更有效。两种药物均结合细胞分裂周期37蛋白并破坏其与热休克蛋白90的相互作用。

要点

  • 基于基因表达特征的计算筛选鉴定出3种驱虫药可显著改变HCC中上调或下调基因的表达。
  • 氯硝柳胺和NEN对HCC细胞的细胞毒性至少比原代人肝细胞高7倍。
  • 口服NEN而非氯硝柳胺可显著减缓小鼠基因诱导性肝肿瘤和患者来源异种移植瘤的生长。

核心结论

  • 在生物信息学搜索中鉴定出驱虫药氯硝柳胺为潜在抗肿瘤药物,其乙醇胺盐NEN生物利用度更高,减缓小鼠肝肿瘤生长更有效。
  • 两种药物均破坏HCC细胞中细胞分裂周期37与热休克蛋白90的相互作用,并伴随下游信号通路抑制。
  • NEN可能对HCC患者的治疗有效。

研究设计与样本

  • 研究检索公共数据库中人HCC标本、HCC细胞系及暴露于各种药物的细胞的信使RNA表达模式。
  • 采用基于Kolmogorov-Smirnov统计量的非参数、基于排序的模式匹配策略鉴定候选药物。
  • 在HCC细胞系(HepG2、Huh7、Hep3B、Hep40和PLC/PRF/5)、原代人肝细胞和2种小鼠HCC模型中评估氯硝柳胺及其乙醇胺盐NEN的抗肿瘤活性。
  • 一种小鼠模型通过流体动力学递送表达活化型Ras(v12)和截短型β-连环蛋白(N90)的睡美人转座子诱导肝肿瘤发生。
  • 另一种小鼠模型通过将患者HCC细胞植入免疫缺陷小鼠肝脏建立患者来源异种移植瘤,用生物发光成像监测肿瘤生长。

主要发现

  • 基于基因表达特征鉴定出3种驱虫药可显著改变HCC中上调或下调基因的表达。
  • 氯硝柳胺和NEN对HCC细胞的细胞毒性至少比原代人肝细胞高7倍。
  • 口服NEN显著减缓小鼠基因诱导性肝肿瘤和患者来源异种移植瘤的生长,而氯硝柳胺未显著减缓,与NEN生物利用度高于氯硝柳胺的观察一致。
  • NEN与索拉非尼联用减缓患者来源异种移植瘤生长的效果优于任一单药。
  • 在HepG2细胞和患者来源异种移植瘤中,给予氯硝柳胺或NEN使HCC中下调的20个基因表达增加、使274基因HCC特征中上调的29个基因表达减少。

关键数值与推荐

  • 氯硝柳胺和NEN对HCC细胞的细胞毒性至少比原代人肝细胞高7倍。
  • 在274基因HCC特征中,给予氯硝柳胺或NEN使20个下调基因表达增加、29个上调基因表达减少。
  • 给予荷患者来源异种移植瘤小鼠NEN可降低Wnt-β-连环蛋白、信号转导及转录激活因子3、AKT-雷帕霉素机制性靶点、表皮生长因子受体-Ras-Raf信号通路中蛋白的表达。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Drug repositioning offers a shorter approval process than new drug development. We therefore searched large public datasets of drug-induced gene expression signatures to identify agents that might be effective against hepatocellular carcinoma (HCC). METHODS: We searched public databases of messenger RNA expression patterns reported from HCC specimens from patients, HCC cell lines, and cells exposed to various drugs. We identified drugs that might specifically increase expression of genes that are down-regulated in HCCs and reduce expression of genes up-regulated in HCCs using a nonparametric, rank-based pattern-matching strategy based on the Kolmogorov-Smirnov statistic. We evaluated the anti-tumor activity of niclosamide and its ethanolamine salt (NEN) in HCC cell lines (HepG2, Huh7, Hep3B, Hep40, and PLC/PRF/5), primary human hepatocytes, and 2 mouse models of HCC. In one model of HCC, liver tumor development was induced by hydrodynamic delivery of a sleeping beauty transposon expressing an activated form of Ras (v12) and truncated β-catenin (N90). In another mouse model, patient-derived xenografts were established by implanting HCC cells from patients into livers of immunocompromised mice. Tumor growth was monitored by bioluminescence imaging. Tumor-bearing mice were fed a regular chow diet or a chow diet containing niclosamide or NEN. In a separate experiment using patient-derived xenografts, tumor-bearing mice were given sorafenib (the standard of care for patients with advanced HCC), NEN, or niclosamide alone; a combination of sorafenib and NEN; or a combination sorafenib and niclosamide in their drinking water, or regular water (control), and tumor growth was monitored. RESULTS: Based on gene expression signatures, we identified 3 anthelmintics that significantly altered the expression of genes that are up- or down-regulated in HCCs. Niclosamide and NEN specifically reduced the viability of HCC cells: the agents were at least 7-fold more cytotoxic to HCCs than primary hepatocytes. Oral administration of NEN to mice significantly slowed growth of genetically induced liver tumors and patient-derived xenografts, whereas niclosamide did not, coinciding with the observed greater bioavailability of NEN compared with niclosamide. The combination of NEN and sorafenib was more effective at slowing growth of patient-derived xenografts than either agent alone. In HepG2 cells and in patient-derived xenografts, administration of niclosamide or NEN increased expression of 20 genes down-regulated in HCC and reduced expression of 29 genes up-regulated in the 274-gene HCC signature. Administration of NEN to mice with patient-derived xenografts reduced expression of proteins in the Wnt-β-catenin, signal transducer and activator of transcription 3, AKT-mechanistic target of rapamycin, epidermal growth factor receptor-Ras-Raf signaling pathways. Using immunoprecipitation assays, we found NEN to bind cell division cycle 37 protein and disrupt its interaction with heat shock protein 90. CONCLUSIONS: In a bioinformatics search for agents that alter the HCC-specific gene expression pattern, we identified the anthelmintic niclosamide as a potential anti-tumor agent. Its ethanolamine salt, with greater bioavailability, was more effective than niclosamide at slowing the growth of genetically induced liver tumors and patient-derived xenografts in mice. Both agents disrupted interaction between cell division cycle 37 and heat shock protein 90 in HCC cells, with concomitant inhibition of their downstream signaling pathways. NEN might be effective for treatment of patients with HCC.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Chen B, Wei W, Ma L, et al. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. Gastroenterology. 2017. PMID: 28284560. doi:10.1053/j.gastro.2017.02.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。